Abstract Library

#3738 Breast neuroendocrine carcinoma – A case report

Introduction: Neuroendocrine breast tumors are a rare entity estimated at 0.1% of all breast tumors.

Conference:

Presenting Author:

Authors: Kaid M, Bengueddache A, Kehili H, Bennaoum A, Bereksi-Reguig F,

Keywords: breast neuroendocrine tumor,

#3384 Rapidly growing Adenomyomatosis of the gallbladder to neuroendocrine carcinoma of the gallbladder: A case report

Introduction: Gallbladder neuroendocrine carcinomas are rare tumors with a prognosis poorer than that of other gallbladder carcinomas. These tumors are often detected late and are difficult to treat.

Conference:

Presenting Author:

Authors: Bengueddache A, Kehili H, Tidjene A, Boudjnan N, Manouni C,

Keywords: Adenomyomatosis of the gallbladder,

#3211 Microscopic resection margin status does not predict long-term survival in small bowel neuroendocrine tumors

Introduction: Small bowel neuroendocrine tumors (SBNETs) are increasing in incidence and are the most common small bowel malignancy. The characteristic nodal mass, which may extend high into the mesentery, can make achieving microscopically negative resection margins difficult without resecting excessive lengths of small bowel.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mentor K, Ammar K, Thakkar R, Farrington E, Buckley E,

Keywords: small bowel, grading, resection margin, survival,

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience

Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dureja S

Authors: Dureja S, Sen I, Pant V, Thak P,

Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,

#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,